Literature DB >> 22123064

Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Yuniel Fernández-Marrero1, Alejandro López-Requena.   

Abstract

The majority of the most effective monoclonal antibodies (mAbs) currently in the clinics bind to cancer or immune cells. Classic mechanisms of cell killing by therapeutic mAbs include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and induction of apoptosis by engagement of specific cell ligands. A few reports have described mAbs whose cytotoxic activity is Fc-independent and that do not induce the morphological and biochemical changes associated with the apoptosis-type of cell death. Even fewer works describe mAbs able to directly induce membrane lesions. Here, we discuss the available data on those molecules and their cell killing activity, with particular attention to the case of a mAb specific for the tumor-associated N-glycolyl (Neu5Gc)-GM3 ganglioside (GM3(Neu5Gc)). Some similarities are found in the cell death pathways triggered by these mAbs, but data are not abundant. We conclude that the usefulness of mAbs with a direct cytotoxic activity for immunotherapeutic strategies deserves deeper research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123064      PMCID: PMC3242839          DOI: 10.4161/mabs.3.6.17770

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  95 in total

Review 1.  An innate sense of danger.

Authors:  Polly Matzinger
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

2.  Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc.

Authors:  Juan P Oliva; Zodilina Valdés; Angel Casacó; Gilmara Pimentel; Joaquín González; Irene Alvarez; Martha Osorio; Milagros Velazco; Mariela Figueroa; Rosa Ortiz; Xiomara Escobar; Maiby Orozco; Julia Cruz; Sonia Franco; Mirtha Díaz; Lourdes Roque; Adriana Carr; Ana M Vázquez; Cristina Mateos; María C Rubio; Rolando Pérez; Luis E Fernández
Journal:  Breast Cancer Res Treat       Date:  2005-12-02       Impact factor: 4.872

3.  Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides.

Authors:  E Moreno; B Lanne; A M Vázquez; I Kawashima; T Tai; L E Fernández; K A Karlsson; J Angström; R Pérez
Journal:  Glycobiology       Date:  1998-07       Impact factor: 4.313

4.  Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death.

Authors:  F Ma; C Zhang; K V Prasad; G J Freeman; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 5.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

6.  In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody.

Authors:  Adriana Carr; Circe Mesa; María del Carmen Arango; Ana María Vázquez; Luis Enrique Fernández
Journal:  Hybrid Hybridomics       Date:  2002-12

7.  Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.

Authors:  Marcelo D Guthmann; Mónica A Castro; Gabriela Cinat; Cecilia Venier; Leonardo Koliren; Roberto J Bitton; Ana María Vázquez; Leonardo Fainboim
Journal:  J Immunother       Date:  2006 Mar-Apr       Impact factor: 4.456

8.  Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes.

Authors:  J Garrigues; U Garrigues; I Hellström; K E Hellström
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

Review 9.  Apoptosis, oncosis, and necrosis. An overview of cell death.

Authors:  G Majno; I Joris
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

10.  IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

Authors:  Sophia N Karagiannis; Marguerite G Bracher; James Hunt; Natalie McCloskey; Rebecca L Beavil; Andrew J Beavil; David J Fear; Richard G Thompson; Nicholas East; Frances Burke; Robert J Moore; David D Dombrowicz; Frances R Balkwill; Hannah J Gould
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

View more
  5 in total

1.  Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Authors:  G M Piperno; A López-Requena; A Predonzani; D Dorvignit; M Labrada; L Zentilin; O R Burrone; M Cesco-Gaspere
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

2.  A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.

Authors:  Ana Victoria Casadesús; Yuniel Fernández-Marrero; Marilyn Clavell; José Alberto Gómez; Tays Hernández; Ernesto Moreno; Alejandro López-Requena
Journal:  Glycoconj J       Date:  2013-04-02       Impact factor: 2.916

3.  Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation.

Authors:  Shuji Matsuoka; Yasuyuki Ishii; Atsuhito Nakao; Masaaki Abe; Naomi Ohtsuji; Shuji Momose; Hui Jin; Hisashi Arase; Koichi Sugimoto; Yusuke Nakauchi; Hiroshi Masutani; Michiyuki Maeda; Hideo Yagita; Norio Komatsu; Okio Hino
Journal:  PLoS One       Date:  2016-03-30       Impact factor: 3.240

4.  Establishment of anti-mesothelioma monoclonal antibodies.

Authors:  Natsuko Mizutani; Masaaki Abe; Shuji Matsuoka; Kazunori Kajino; Midori Wakiya; Naomi Ohtsuji; Ryo Hatano; Chikao Morimoto; Okio Hino
Journal:  BMC Res Notes       Date:  2016-06-24

5.  Generation and characterization of a IgG monoclonal antibody specific for GM3 (NeuGc) ganglioside by immunizing β3Gn-T5 knockout mice.

Authors:  Dongwei He; Xiaoyan Fan; Boyi Liu; Yiqing Tian; Xiangmei Zhang; Lin Kang; Yan Tai; Shuzhen Liu; Qian Wang; Qingxia Li; Jianhui Cai
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.